SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Array BioPharma Inc. (Nasdaq: ARRY) To Contact Brower Piven Before The Lead Plaintiff Deadline

STEVENSON, Md., Nov. 30, 2017 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Colorado on behalf of purchasers of Array BioPharma Inc. (Nasdaq:ARRY) (“Array” or the “Company”) securities during the period between December 16, 2015 and March 17, 2017, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until January 22, 2018 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.  The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action.  The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Array securities during the Class Period.  Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.  No class has yet been certified in the above action.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Array’s NEMO study failed to show sufficient clinical benefit of the binimetinib new drug application in use for patients with NRAS-mutant melanoma, and the Company was aware that this lack of supporting clinical data would not be sufficient to receive U.S. Food and Drug Administration (“FDA”) approval of binimetinib in use for patients with NRAS-mutant melanoma.

According to the complaint, following a March 19, 2017 press release announcing it had withdrawn from the FDA Division of Oncology Products 2 its new drug application for binimetinib monotherapy for the treatment of NRAS-mutant melanoma, the value of Array shares declined significantly.

If you have suffered a loss in excess of $100,000 from investment in Array securities purchased on or after December 16, 2015 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/casesandinvestigations.html.  You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.  If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice.  You need take no action at this time to be a member of the class.

CONTACT:  Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]